The Clinical Study Of RIF And ATRA In The Induction Treatment Of Acute Promyelocytic Leukemia

ObjectiveThis study is to analyse comparatively the clinical efficacy of RIF and ATO in the treatment of acute promyelocytic leukemia.To study further the exact effect of RIF in the induction treatment of acute promyelocytic leukemia,and provide reference for the optimization solutions of acute promyelocytic leukemia.MethodsThis randomized,single-blind,parallel-controlled clinical study,30 cases were included,and randomly divided into oral compound huangdai Tablet and Retinoic acid induced by treatment with compound huangdai tablets(the treatment group)in 14 cases,and arsenic trioxide combined withTretinoin-based programme of arsenic trioxide Group(control group)in 16 cases.Summary in clinical symptoms,blood analysis,and bone marrow morphology,genes and chromosomes,coagulation,hepatic and renal function and otheradverse events of all patients before and after induction therapy,usingstatistical methods to analyse two groups of patients,then concluded.Results1.After the induction therapy,the complete remission rate of thetreatment group is 92.8%,while the controlled group is 100%,not statistically significant.The treatment group takes 43.76±9.51 days to achieve complete remission,while the controlled group takes 39.96±8.60 days.The CR time of the two groups is statistical,indicating induced remission rates are similar in both groups,whereas the CR time of the RIF group is slightly longer than the ATO group's.2.After induction of remission,the PML-RAR? gene transfer rate in both group have no significant difference.Until the end of the study,the two groups have sustained remission without recurrence in molecular and hematology.3.The two groups have no difference in recovery time of PT and APTT,while the time of Fib and d-dimer are statistically significant.So RIF is contributed to restore the blood coagulation function,and can reduce the amount of blood product in the treatment.4.The incidence of DIC in both groups has no difference,characterized by skin and mucous membrane bleeding,bleeding gums,blood in.5.In the course of induced treatment,the high white blood cell in peak,maintaining time and related clinical feathers,both groups have no statistically significantdifferences.6.The incidence of ECG abnormalities,liver damage,gastrointestinal reaction and other adverse reactions has no significant difference in both groups.Withdrawal or symptomatic treatments can return to normal.Description of RIF and ATO has similar security.Conclusion1.The rate of complete remission of RIF is similar to ATO group's,but with slightly longer remission time.2.The induction programme based on RIF may reduce the recover time of blood coagulation,the appearance of early bleeding and related complications,and reduction in the treatment of blood products transfusion.3.The incidence of ECG abnormalities,liver damage,gastrointestinal and other side effects in both groups has no significant differences and description which is mainly for RIF has similar security with ATO.Therefore,the induction programme based on RIF is feasible,with RIF can be used as a full oral therapy in clinical induced treatment of acute promyelocytic leukemia.